Skip to main content
Britannia Life Sciences logo

Britannia Life Sciences — Investor Relations & Filings

Ticker · BLAB ISIN · CA11042D1087 LEI · 549300PN0TMPKNE2R614 CSE Professional, scientific and technical activities
Open in API
Filings indexed 130 across all filing types
Latest filing 2026-05-21 Transaction in Own Shar…
Country CA Canada
Listing CSE BLAB

About Britannia Life Sciences

https://britannia.life/

Britannia Life Sciences operates as a global, vertically diversified product development platform, offering an integrated suite of services that function as a "one-stop-shop" across the entire product lifecycle, from concept to consumer. The company specializes in quality assurance, safety assessment, regulatory compliance, and comprehensive product testing. Core services are delivered through an ISO 17025 accredited laboratory, supporting businesses in the cosmetics, consumer packaged and household goods, nutraceutical, food, and general wellness sectors. The platform includes specialized divisions such as Britannia Labs, which serves the global cannabis industry, and Proof Wellness, an online marketplace for CBD consumers. The company focuses on leveraging its expertise to support clients primarily targeting the UK and European markets.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Transaction in Own Shares Classification · 90% confidence The document is a corporate update press release (via Newsfile) detailing the company’s asset position and strategic direction, with the key announcement being the Board’s approval to commence a normal course issuer bid (NCIB) to repurchase its own shares. It does not contain full financial statements or call transcripts, nor is it an annual or interim report. This type of share repurchase program announcement falls under ‘Transaction in Own Shares’ (POS).
2026-05-21 English
News release - English.pdf
Transaction in Own Shares Classification · 85% confidence The document is a press release providing a corporate update that primarily announces the board’s approval and commencement of a Normal Course Issuer Bid (NCIB), detailing the proposed share repurchase program (maximum shares, duration, funding, etc.). This is not a financial report, governance guideline, or earnings announcement. It is a transaction in own shares (share buyback) announcement. Therefore, it fits the “Transaction in Own Shares” category (Code: POS).
2026-05-21 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Form of Proxy' for Britannia Life Sciences Inc. for an upcoming Annual General Meeting. It provides instructions for shareholders to appoint a proxyholder and vote on specific agenda items like the election of directors and appointment of auditors. This document is a standard solicitation material sent to shareholders to request their votes, which falls under the definition of Proxy Solicitation & Information Statement.
2026-02-03 English
Other.pdf
Regulatory Filings Classification · 95% confidence The document is a 'Request for Financial Statements' form, which is a standard administrative document used by shareholders to opt-in to receive future financial reports. It does not contain financial data, audit results, or management analysis, nor is it an announcement of a specific report's release. It is a routine regulatory/administrative communication between the issuer and shareholders, fitting best under the 'Regulatory Filings' category as a miscellaneous corporate document.
2026-02-03 English
Notice of meeting - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' for Britannia Life Sciences Inc. It outlines the date, time, and purpose of the meeting (electing directors, appointing auditors, etc.) and provides instructions for shareholders to vote via proxy. This document is a standard proxy solicitation material sent to shareholders to inform them of the upcoming meeting and request their votes, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement.
2026-02-03 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Management Information Circular' for Britannia Life Sciences Inc., dated January 22, 2026, for an Annual General Meeting (AGM) to be held on February 24, 2026. It contains proxy solicitation materials, details on the business of the meeting (election of directors, appointment of auditors), executive compensation disclosures, and corporate governance information. This is a classic Proxy Solicitation and Information Statement used to request shareholder votes for an upcoming meeting.
2026-02-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.